Oncology Institute Q2 FY26 net loss narrows 42.4% to $9.79 million; revenue rises 34.6% to $161.28 million
Reuters2026/08/06 21:46- The Oncology Institute posted a GAAP net loss of $9.79 million for the quarter ended June 30, 2026, narrowing from $17.01 million a year earlier.
- Revenue climbed 34.6% to $161.28 million, driven by specialty pharmacy up 57.6% to $98.61 million.
- Patient services revenue rose 5.3% to $58.83 million, as capitation gains were partially offset by lower fee-for-service activity.
- Adjusted EBITDA swung to a gain of $229,000 from a loss of $4.09 million, as SG&A fell 3.9 percentage points to 18.6% of revenue.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP Avengers claims holding 10,000 XRP could yield $1 million, community reacts
AI computing power demand ignites nuclear capital enthusiasm: Holtec (HNUC.US) plans IPO to raise 900 million dollars, targeting a 10 billion dollar valuation.
Nuclear supplier Holtec is seeking to raise up to $900 million through a U.S. initial public offering, as companies aim to profit from the growing electricity demand driven by data centers.
Longest in Five Years! US Stock Earnings Upward Revision Trend Hits Record Since 2021, May Signal Another Profitable Earnings Season Ahead
Supported by strong corporate earnings prospects, U.S. stocks are demonstrating considerable resilience and are withstanding the impact of rising inflationary pressures.
Middle East Turmoil, Higher Crude Bills Damp European Bourses Midday
Crypto prices
More
